MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms

This policy covers non-NGS single- or multi-gene molecular testing for diagnosis of BCR-ABL-negative MPNs when performed per WHO/ICC diagnostic criteria, after BCR-ABL assessment (except when only PV is suspected), using assays with sensitivity to detect VAF ≥4%, and following a sequential reflexive testing approach for single-gene tests. Panels must include minimum necessary genes per the suspected subtype (e.g., JAK2 V617F and exon 12, CALR, MPL; CSF3R when CNL suspected), tests must be analytically and clinically validated with a completed technical assessment, and testing for MRD or test-of-cure is excluded.

"Patient is being evaluated for a BCR-ABL-negative myeloproliferative neoplasm (MPN) according to national or international consensus diagnostic criteria (e."

Sign up to see full coverage criteria, indications, and limitations.